Website www.pharmacosmos.com Founded 1965 Type of business Private | Headquarters Holbæk, Denmark Number of employees 170 (2017) | |
 | ||
Industry Pharmaceuticals, Healthcare Key people Axel Kierkegaard (Chairman of the Board), Lars Christensen (President and CEO) | ||
Pharmacosmos is considered a world leading authority in treatment of iron deficiency anaemia.
Contents
Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, Germany, UK and US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.
Pharmacosmos employs 170 people.
Company profile
Pharmacosmos was founded in Denmark in 1965 by Henry Marinus Christensen, M.D., Ph.D.
Operations
Pharmacosmos' corporate headquarters, manufacturing facilities and research laboratories are located in Holbaek, Denmark (Scandinavia). The company has its own marketing, sales and services operations in Denmark and United Kingdom. In other geographies, the company partners with other pharmaceutical companies responsible for local marketing, sales and distribution of its pharmaceuticals brands. The company does not disclose its revenues.
Manufacturing facilities
Pharmacosmos' manufacturing facility is approved according to current Good Manufacturing Practice (GMP) by the European Medicines Agency (EMA) and by the U.S. Food and Drug Administration (FDA).
Research and development
The company has an ongoing clinical development program aimed at improving treatment options for patients suffering from iron deficiency.